Meibomian Gland Outcome Measures in Dry Eye Treatment Trials
Journal of Clinical Medicine · 25.05.2026 · 15 (11) · 4093
DOI: 10.3390/jcm15114093 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.05.2026. Verfasst von Shora M Ansari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Southern California College of Optometry, Marshall B. Ketchum University, Fullerton, CA 92831, USA. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: This review considered meibomian gland functional assays, reported in recent dry eye treatment trials, that have potential as a clinical/physiological measure in a Core Outcome Set in dry eye clinical trials. The focus was on clinical methods that can be applied globally by trained clinicians.
Methods
An electronic search of the MEDLINE database (via PubMed) was conducted to identify randomized controlled trials published in English between 1 January 1995 and 11 December 2025. The search strategy used the terms (meibomian OR meibography) AND treatment. Studies were included if they reported outcomes related to meibum secretion and/or meibomian gland expressibility in human participants. Moreover, a retrospective chart review was undertaken from previously unpublished meibum grading data to determine whether opacity and viscosity grades for meibum are correlated.
Results
98 studies were included for analysis The grading systems of Bron and co-workers, combined with that of the similar MGD Workshop report, were the most prevalent (n = 48), followed by Lane and co-workers (n = 23) and Shimazaki and co-workers (n = 10). Expressibility grading systems were most prevalent for Pflugfelder et al. (n = 33), followed by Blackie-Korb (n = 19) and Author defined (n = 17). The retrospective analysis of 69 charts suggests high correlation between meibum opacity and viscosity (Pearson’s r = 0.904, p < 0.001. 95% CI 0.849–0.940).
Conclusions
Grading meibum quality is important in dry eye diagnosis and treatment. A modification of the MGD Workshop system appears useful as a core outcome set parameter in dry eye treatment trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Southern California College of Optometry, Marshall B. Ketchum University, Fullerton, CA 92831, USA.
- Independent Researcher, Pico Rivera, CA 90660, USA.
- Department of Mathematics, California State University, Fullerton, CA 90802, USA.
ORCID-Profile: Shora M Ansari
Zitieren
APA
Ansari, S. M., Jiang, J. R., Nguyen, A. L., & Paugh, J. R. (2026). Meibomian Gland Outcome Measures in Dry Eye Treatment Trials. Journal of Clinical Medicine, 15(11), 4093. https://doi.org/10.3390/jcm15114093
Vancouver
Ansari SM, Jiang JR, Nguyen AL, Paugh JR. Meibomian Gland Outcome Measures in Dry Eye Treatment Trials. Journal of Clinical Medicine. 2026;15(11):4093. doi:10.3390/jcm15114093
BibTeX
@article{Ansari2026,
author = {Ansari, Shora M and Jiang, Jay Ruzhang and Nguyen, Andrew Loc and Paugh, Jerry R},
title = {Meibomian Gland Outcome Measures in Dry Eye Treatment Trials},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {11},
pages = {4093},
doi = {10.3390/jcm15114093}
}
EUVIMED